Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib + paclitaxel versus placebo + paclitaxel as first-line treatment for metastatic triple-negative breast cancer
2014-002230-32Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Cobimetinib + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Oct 2014; status: completed.
02
Drugs
cobimetinibpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2014-002230-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002230-32.